Keith Greenfield

Keith Greenfield is the current Director at Xylyx Bio. Keith has also previously worked at Aloe Attiva, Xylyx Bio, Inc., Hoo.be by FNL Technologies, AZTherapies, Inc., Hessian-Labs, Phage Nova Bio, Inc., NanoTomer, The Dover Group, and IQuum. Keith was with IQuum from January 1994 to June 2014, and was their Co-Founder, Director, and Executive Vice President Corporate Development. IQuum was successfully sold to Roche Molecular Diagnostics for $485 million while Keith was a part of the team that executed the transaction. In addition to being a part of the execution team for this transaction, Keith was also instrumental in terms of strategic consulting, business planning, sales strategy development, and structuring commercial transactions, while maintaining their role as an investor liaison between all shareholders.

Keith Greenfield graduated from Questrom School of Business with a Bachelor of Applied Science in Finance.